AstraZeneca (AZN) Investor update summary

Portfolio and Pipeline Progress

• Multiple new molecular entities approved, including Baxfendy, with positive CHMP for camizestrant and strong global regulatory momentum.

• Significant advances in weight management, radioconjugates, ADCs, and IO bispecifics, with several assets moving into phase III.

• Robust pipeline momentum with a positive phase III readout nearly every month over the past three years.

• Alexion rare disease portfolio assets are transitioning from early promise to clinical reality.

• Over 80 abstracts accepted at ASCO 2026, with 52 poster and 25 oral presentations across more than 15 tumor types.

Strategic Revenue and Growth Ambitions

• Targeting $80bn in total revenue by 2030, with sustained growth beyond 2030, driven by a robust pipeline and not dependent on future M&A.

• Key contributors to revenue include new molecular entities and established brands across oncology, biopharma, and rare diseases.

• Continued investment in next-generation therapies such as ADCs, radioconjugates, cell and gene therapies, and weight management.

• R&D expenses expected to remain at the upper end of low-20% of total revenue due to strong clinical trial execution.

• Multiple phase III readouts and regulatory milestones expected in the second half of the year and beyond.

Pipeline Momentum and Clinical Milestones

• Multiple Phase III readouts expected in 2026, representing a combined risk-adjusted peak year revenue opportunity of over $10bn.

• Key trials include EMERALD-3 (liver cancer), AVANZAR, VOLGA, and SERENA-4, spanning oncology, biopharma, and rare disease indications.

• Robust pipeline momentum with a positive phase III readout nearly every month over the past three years.

• Ongoing evidence generation for TACE and TARE, and segmentation strategies in IO and bispecifics remain a focus.

• SERENA-4 and SERENA-6 trials are positioned to inform future endocrine therapy backbones in breast cancer.